T. Rowe Price Investment Management Inc. Has $127.51 Million Holdings in Sarepta Therapeutics, Inc. $SRPT

Key Points

• T. Rowe Price Investment Management Inc. increased its stake in Sarepta Therapeutics by 2.1% during the first quarter, owning nearly 2 million shares worth approximately $127.5 million.
• Sarepta Therapeutics reported a 68.4% increase in revenue year-over-year for the quarter, with earnings per share of $2.02 that surpassed analysts' expectations.
• The biotechnology company has a current market cap of $1.96 billion and analysts maintain a consensus target price of $43.50 on its stock.

T. Rowe Price Investment Management Inc. raised its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 2.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,997,991 shares of the biotechnology company's stock after purchasing an additional 41,408 shares during the period. T. Rowe Price Investment Management Inc. owned 2.03% of Sarepta Therapeutics worth $127,512,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of SRPT. Mariner LLC lifted its holdings in shares of Sarepta Therapeutics by 14.8% in the 4th quarter. Mariner LLC now owns 8,042 shares of the biotechnology company's stock valued at $978,000 after buying an additional 1,035 shares during the period. Jump Financial LLC acquired a new position in Sarepta Therapeutics in the fourth quarter valued at approximately $221,000. Dimensional Fund Advisors LP boosted its position in shares of Sarepta Therapeutics by 10.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 310,810 shares of the biotechnology company's stock worth $37,791,000 after purchasing an additional 30,615 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Sarepta Therapeutics by 2.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 241,663 shares of the biotechnology company's stock valued at $29,385,000 after acquiring an additional 5,130 shares during the period. Finally, Pinebridge Investments L.P. raised its position in Sarepta Therapeutics by 42.7% in the 4th quarter. Pinebridge Investments L.P. now owns 25,143 shares of the biotechnology company's stock valued at $3,057,000 after purchasing an additional 7,520 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Scotiabank raised shares of Sarepta Therapeutics from a "sector perform" rating to a "sector outperform" rating and set a $80.00 price target for the company in a research report on Friday, June 6th. The Goldman Sachs Group boosted their target price on Sarepta Therapeutics to $19.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. HC Wainwright restated a "sell" rating on shares of Sarepta Therapeutics in a research note on Monday. Baird R W cut Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, July 18th. Finally, Wall Street Zen raised shares of Sarepta Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Eight investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and six have issued a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $43.50.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT traded up $0.19 on Tuesday, hitting $18.25. The company had a trading volume of 7,226,033 shares, compared to its average volume of 6,265,511. The company has a market cap of $1.78 billion, a PE ratio of -20.98 and a beta of 0.46. The business has a 50 day moving average of $17.93 and a 200 day moving average of $49.16. Sarepta Therapeutics, Inc. has a 52-week low of $10.41 and a 52-week high of $140.97. The company has a current ratio of 2.89, a quick ratio of 1.81 and a debt-to-equity ratio of 0.84.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $1.13. The company had revenue of $611.09 million for the quarter, compared to analysts' expectations of $530.66 million. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The firm's revenue for the quarter was up 68.4% compared to the same quarter last year. During the same period last year, the company earned $0.07 EPS. As a group, equities analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.